Current Issue
Volumes and Issues
For Authors
Manuscript Guidelines
Review Process
Conflict of Interest
Copyright
About the Journal
Editorial Board
Aim and Scope
Policy and Ethical Guidelines
Promotion of the Journal
Print-Version Subscription
Publisher and Contact Information
Contact Information
Sign in
ORIGINAL ARTICLE
EFFICIENCY OF DISTORTION PRODUCT OTOACOUSTIC EMISSIONS AS A METHOD FOR OTOTOXICITY MONITORING
1
ENT-Department, YSMU, Armenia
2
ENT-Department, YSMU, Nairi MC, Armenia
3
CI Centre, National Research for Audiology and Hearing Rehabilitation, Russia
4
ENT Department, Erebouni MC, Armenia
5
Department of Chemotherapy, Nairi MC, Armenia
6
ENT-Department, YSMU, Erebouni MC, Armenia
A - Research concept and design; B - Collection and/or assembly of data; C - Data analysis and interpretation; D - Writing the article; E - Critical revision of the article; F - Final approval of article;
Submission date: 2020-06-30
Final revision date: 2020-09-09
Acceptance date: 2020-09-09
Publication date: 2020-12-07
J Hear Sci 2020;10(3):51-57
KEYWORDS
TOPICS
ABSTRACT
Objective:
The purpose of this study is to describe hearing and auditory functional changes in patients receiving platinum-based treatments and to estimate the capacity of DPOAE and pure tone audiometry in evaluating ototoxicity as well as evaluating the risk factors of ototoxicity.
Design:
Standard pure tone audiometry at frequencies of 250–8000 Hz, and also at 12000 Hz and DPOAE recording were tested prior to starting chemotherapy and once again at the end of our program.
Study sample:
56 patients receiving cisplatin and carboplatin were tested.
Results:
At the conventional frequencies, ototoxicity occurred in 6 (33%) of 18 patients who received cisplatin and in 12 (32%) of 38 carboplatin patients. Ototoxic hearing loss only at 12000 Hz occurred in 5 (28%) patients who received cisplatin and in 2 (5%) carboplatin patients. DPOAEs declined in 9 (75%) of 12 patients who received cisplatin and in 7 (44%) of 16 carboplatin patients. Increased dosage of platinum brought about hearing loss. Our study also investigated the initial hearing threshold as a risk factor for ototoxicity development.
Conclusion:
Ototoxicity monitoring ought to be an important and valuable option in patients being treated with chemotherapy.
The purpose of this study is to describe hearing and auditory functional changes in patients receiving platinum-based treatments and to estimate the capacity of DPOAE and pure tone audiometry in evaluating ototoxicity as well as evaluating the risk factors of ototoxicity.
Design:
Standard pure tone audiometry at frequencies of 250–8000 Hz, and also at 12000 Hz and DPOAE recording were tested prior to starting chemotherapy and once again at the end of our program.
Study sample:
56 patients receiving cisplatin and carboplatin were tested.
Results:
At the conventional frequencies, ototoxicity occurred in 6 (33%) of 18 patients who received cisplatin and in 12 (32%) of 38 carboplatin patients. Ototoxic hearing loss only at 12000 Hz occurred in 5 (28%) patients who received cisplatin and in 2 (5%) carboplatin patients. DPOAEs declined in 9 (75%) of 12 patients who received cisplatin and in 7 (44%) of 16 carboplatin patients. Increased dosage of platinum brought about hearing loss. Our study also investigated the initial hearing threshold as a risk factor for ototoxicity development.
Conclusion:
Ototoxicity monitoring ought to be an important and valuable option in patients being treated with chemotherapy.
REFERENCES (20)
1.
Reavis KM, McMillan G, Austin D, et al. Distortion-product otoacoustic emission test performance for ototoxicity monitoring. Ear Hear, 2011; 32(1): 61–74.
2.
Hartmann JT, Lipp HT. Toxicity of platinum compounds. Expert Opin Pharmacother, 2003; 4: 889–901.
3.
Macdonald RM, Harrison RV, Wake M, Bliss B, Macdonald RE. Ototoxicity of carboplatin: comparing animal and clinical models at the Hospital for Sick Children. J Otolaryngol, 1994; 23(3): 151–9.
4.
Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer, 2004; 40(16): 2445–51.
5.
Rademaker-Lakhai JM, Crul M, Zuur L. Relationship between cisplatin administration and the development of ototoxicity. J Clin Oncol, 2006; 24(6): 918–24.
6.
Fausti SA, Larson VD, Noffsinger D, Wilson RH, Phillips DS, Fowler CG. High-frequency audiometric monitoring strategies for early detection of ototoxicity. Ear Hear, 1994; 15(3): 232–9.
7.
Ress BD, Sridhar KS, Balkany TJ, Waxman GM, Stagner BB, Lonsbury-Martin BL. Effects of cis-platinum chemotherapy on otoacoustic emissions: the development of an objective screening protocol. Otolaryngol Head Neck Surg, 1999; 121(6): 693–701.
8.
Wright CG, Schaefer SD. Inner ear histopathology in patients treated with cis-platinum. Laryngoscope, 1982; 92(12): 1408–13.
9.
Knight KR, Kraemer DF, Winter C, Neuwelt EA. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol, 2007; 25(10): 1190–95.
10.
Rybak LP, Whitworth CA. Ototoxicity: therapeutic opportunities. Drug Discovery Today; 2005; 10: 1313–21.
11.
Gorga MP, Neely ST, Bergman B, et al. Otoacoustic emissions from normal-hearing and hearing-impaired subjects: distortion product responses. J Acoust Soc Am, 1993; 93: 2050–60.
12.
Stavroulaki P, Apostolopoulos N, Segas J, Tsakanikos M, Adamopoulos G. Evoked otoacoustic emissions: an approach for monitoring cisplatin induced ototoxicity in children. Int J Pediatr Otorhinolaryngol, 2001; 59(1): 47–57.
13.
Stavroulaki P, Vossinakis IC, Dinopoulou D, Doudounakis S, Adamopoulos G, Apostolopoulos N. Otoacoustic emissions for monitoring aminoglycoside-induced ototoxicity in children with cystic fibrosis. Arch Otolaryngol Head Neck Surg, 2002; 128(2): 150–155.
14.
BIAP Recommendation 02/1: Audiometric Classification of Hearing Impairments (1996). http://www.biap.org/en/recomma....
15.
American Speech-Language-Hearing Association (ASHA).1994. Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy. 36: 11–19.
16.
Beattie RC, Kenworthy OT, Luna CA. Immediate and short-term reliability of distortion-product otoacoustic emissions. Int J Audiol, 2003; 42: 348–54.
17.
Reavis KM, Phillips DS, Fausti SA, et al. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss. Ear Hear, 2008; 29: 875–93.
18.
van der Hulst RJ, Dreschler WA, Urbanus NA. High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives. Ann Otol Rhinol Laryngol, 1988; 977(2 Pt 1): 133–7.
19.
Bokemeyer C, Berger CC, Hartmann JT, et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer, 1998; 77: 1355–62.
20.
Schaefer SD, Post JD, Close LG, Wright CG. Ototoxicity of lowand moderate-dose cisplatin. Cancer, 1985; 56: 1934–9.
Share
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
